A reasonable monitoring approach might look like this: First 3 Months: Week 2: Basic kidney function and urine test Month 1: B12 level, homocysteine, kidney function Month 3: Full panel repeat Months 4-12: Every 3 months: Comprehensive monitoring Monthly kidney checks if function is below 60 Adjust doses based on trends After Year 1: Every 6 months: Full monitoring panel Annual: More advanced tests if needed Ongoing: Pay attention to how you feel and any symptoms How can you actually implement these strategies without it becoming overwhelming or expensive
Mechanistic Focus in Research Within controlled laboratory environments, AOD-9604 is commonly studied in relation to peptide-mediated signalling pathways and molecular regulatory systems
Washout Periods After administration of glucocorticoids, an Adverse Analytical Finding (positive doping test) can be reached for different periods of time after administration, depending on the glucocorticoid administered and the dose
Controls received HC only
Because the incidence of B12 deficiency is so high among thyroid patients I often recommend that every thyroid patient takes a B12 supplement (or at least takes B12 in one or more of their supplements) in some form
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy